Skip to main content

Allschwil, Switzerland – 10 June, 2025 – Phialogics AG announces the appointment of Dr. Debra Barker as Chief Medical Officer.

Dr. Barker joins Phialogics with over 30 years of experience in drug development, spanning both the pharmaceutical industry and academic research. A seasoned physician and life sciences executive, she has held leadership roles across global pharma and biotech, including as Head of Development for Immunology and Infectious Diseases at Novartis. Her broad expertise includes guiding assets through late-stage development and registration in immunology, oncology, and infectious diseases. She has also contributed to IPOs, strategic partnerships, and non-dilutive funding initiatives.

At Phialogics, Dr. Barker will work closely with the scientific team to shape the clinical pipeline and strategy, reinforcing the company’s mission to restore immune homeostasis in complex disease areas.

I am absolutely thrilled to welcome Debra to our team. Her deep expertise in immunology and clinical development will be invaluable as we continue to scale and evolve our pipeline

Dr. Natalia NovacChief Executive Officer and Chairwoman of Phialogics AG

I’m delighted to be working with Phialogics in advancing its bold mission to re-establish immune homeostasis in challenging disease settings. I look forward to leveraging my drug development experience to guide portfolio design and clinical strategy as we bring these promising therapies closer to patients.

Dr. Debra BarkerChief Medical Officer Phialogics

About Phialogics

Phialogics is an innovative start-up in the field of autoimmune diseases. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in Basel (CH) and Heidelberg (GER) is committed to making a decisive contribution to the autoimmune disease space. The founding team is backed by strong Scientific Advisory and Supervisory Boards, which puts the company in a good position to move fast on the lead candidate and develop novel biologics.

We are thrilled to welcome Debra and wish the whole team a great success!

Share this article

View all news

Sign up to receive our newsletter in your inbox.

Share